Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
Merck KGaA’s (OTC:MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring…
Adagene Inks Third Cancer Trial Collaboration With Merck
Adagene Inc (NASDAQ:ADAG) has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK). The agreement includes…
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA
Adagene Inc. (“Adagene”) (NASDAQ:ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today
Werewolf Therapeutics Inks Solid Tumor Trial Collaboration With Merck
Werewolf Therapeutics Inc (NASDAQ: HOWL) has entered into a
Werewolf Therapeutics Announces Clinical Trial Collaboration With Merck On Its WTX-124 INDUKINE Program
Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment
Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and selling.
Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett’s Berkshire Adjusted Its Portfolio In Q2
Warren Buffett-led Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) sharply lowered its exposure in General Motors Co (NYSE:
Merck’s Belzutifan Wins FDA Approval As First Drug For Rare VHL Tumors
The FDA on Friday approved Merck & Co Inc’s (NYSE:MRK) belzutifan for patients with the rare disorder known as von Hippel-Lindau…
The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among those reporting during the week.